ALINA

NCT03456076 📎

Regimen

Experimental
Alectinib
Control
Platinum-Based Chemotherapy

Population

completely resected ALK+ NSCLC, stage IB (≥4 cm) / II / IIIA, adjuvant setting

Key finding

Adjuvant alectinib in resected ALK+ NSCLC: DFS HR 0.24 vs chemo.

Source: PMID 38598794

Timeline

  • Enrollment start: 2018-08-16 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source